sequencing: search

First Whole Cancer Genome Sequenced

dooling writes "A paper detailing the sequencing of the first human cancer genome will be published in the 6 November 2008 issue of Nature. This is not only the first cancer genome published, it is the first female genome as well. You can read the paper's abstract, DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome, or the story in Science News. This issue of Nature also has articles on the sequencing of the first African and Asian genomes. The sequencing in all three articles was done using the Illumina Genome Analyzer, one of the massively parallel, next-generation genome sequencing platforms."

Complete Genomics Chooses Isilon IQ to Power World's First Complete Human Genome Sequencing Service

PRNewswire-FirstCall/ -- Isilon(R) Systems (Nasdaq: ISLN), the leader in clustered storage, today announced that Complete Genomics, the world's first provider of large-scale human genome sequencing services, has deployed more than 700 Terabytes of Isilon IQ clustered storage to unify its vast stores of mission-critical genetic data and help power its groundbreaking DNA sequencing pipeline. With Isilon IQ, Complete Genomics has accelerated its research and development operations -- including DNA sequencing, software development and large-scale bioinformatics simulations -- while eliminating the requirement for a full-time storage administrator. Additionally, Isilon IQ, featuring its OneFS(R) operating system software, provides Complete Genomics' massive Linux clustered compute farm with a centralized, near-line storage archive for immedia

Complete Genomics Chooses Isilon IQ to Power World's First Complete Human Genome Sequencing Service

SEATTLE, Nov. 3 /PRNewswire-FirstCall/ -- Isilon(R) Systems , the leader in clustered storage, today announced that Complete Genomics, the world's first provider of large-scale human genome sequencing services, has deployed more than 700 Terabytes of Isilon IQ clustered storage to unify its vast stores of mission-critical genetic data and help power its groundbreaking DNA sequencing pipeline. With Isilon IQ, Complete Genomics has accelerated its research and development operations -- including DNA sequencing, software development and large-scale bioinformatics simulations -- while eliminating the requirement for a full-time storage administrator. Additionally, Isilon IQ, featuring its OneFS(R) operating system software, provides Complete Genomics' massive Linux clustered compute farm with a centralized, near-line storage archive for immed

Complete Genomics Chooses Isilon IQ to Power World's First Complete Human Genome Sequencing Service

Pioneer in DNA Sequencing Deploys Clustered Storage to Help Redefine the Economics of Large-Scale Sequencing

Complete Genomics Chooses Isilon IQ to Power World's First Complete Human Genome Sequencing Service

Pioneer in DNA Sequencing Deploys Clustered Storage to Help Redefine the Economics of Large-Scale Sequencing

Complete Genomics Chooses Isilon IQ to Power World's First Complete Human Genome Sequencing Service

Pioneer in DNA Sequencing Deploys Clustered Storage to Help Redefine the Economics of Large-Scale Sequencing SEATTLE, Nov. 3

Complete Genomics Chooses Isilon IQ to Power World's First Complete Human Genome Sequencing Service

Pioneer in DNA Sequencing Deploys Clustered Storage to Help Redefine the Economics of Large-Scale Sequencing

Complete Genomics Chooses Isilon IQ to Power World's First Complete Human Genome Sequencing Service

Pioneer in DNA Sequencing Deploys Clustered Storage to Help Redefine the Economics of Large-Scale Sequencing

Illumina's human genome sequencing studies published in Nature

Illumina announced that the November 6, 2008 issue of Nature published sequencing results of the first Yoruban human genome. The study was completed by Illumina scientists and collaborators at the Wellcome Trust Sanger Institute and generated greater than 30x average coverage of the genome. Four million single-nucleotide polymorphisms (SNPs), including one million novel SNPs, and 400,000 structural variants were identified. The Yoruban study and two other papers--by researchers at Beijing Genomics Institute (BGI) and Washington University--featured in the same November 6 issue of Nature all used the Illumina Genome Analyzer to complete the sequencing studies. This marks the first time that three human genome studies--including the first Asian individual, the first cancer patient, and the first African male--have been simultaneously publis

Illumina Announces Breakthrough Human Genome Sequencing Studies Published in Nature

today announced that the November 6, 2008 issue of Nature published sequencing results of the first Yoruban human genome. The study was completed by Illumina scientists and collaborators at the Wellcome Trust Sanger Institute and generated greater than 30x average coverage of the genome. Four million single-nucleotide polymorphisms (SNPs), including one million novel SNPs, and 400,000 structural variants were identified. The Yoruban study and two other papers--by researchers at Beijing Genomics Institute (BGI) and Washington University--featured in the same November 6 issue of Nature all used the Illumina Genome Analyzer to complete the sequencing studies. This marks the first time that three human genome studies--including the first Asian individual, the first cancer patient, and the first African male--have been simultaneously published

Illumina Announces Breakthrough Human Genome Sequencing Studies Published in Nature

Illumina (NASDAQ: ILMN) today announced that the November 6, 2008 issue of Nature published sequencing results of the first Yoruban human genome. The study was completed by Illumina scientists and collaborators at the Wellcome Trust Sanger Institute and generated greater than 30x average coverage of the genome. Four million single-nucleotide polymorphisms (SNPs), including one million novel SNPs, and 400,000 structural variants were identified. The Yoruban study and two other papers--by researchers at Beijing Genomics Institute (BGI) and Washington University--featured in the same November 6 issue of Nature all used the Illumina Genome Analyzer to complete the sequencing studies. This marks the first time that three human genome studies--including the first Asian individual, the first cancer patient, and the first African male--have been

Illumina Announces Breakthrough Human Genome Sequencing Studies Published in Nature

SAN DIEGO--(BUSINESS WIRE)--Nov 7, 2008 - Illumina (NASDAQ: ILMN) today announced that the November 6, 2008 issue of Nature published sequencing results of the first Yoruban human genome. The study was completed by Illumina scientists and collaborators at the Wellcome Trust Sanger Institute and generated greater than 30x average coverage of the genome. Four million single-nucleotide polymorphisms (SNPs), including one million novel SNPs, and 400,000 structural variants were identified. The Yoruban study and two other papers--by researchers at Beijing Genomics Institute (BGI) and Washington University--featured in the same November 6 issue of Nature all used the Illumina Genome Analyzer to complete the sequencing studies. This marks the first time that three human genome studies--including the first Asian individual, the first cancer patie

Illumina Announces Breakthrough Human Genome Sequencing Studies Published in Nature

Three Landmark Studies of Independent Human Genomes Carried Out on Illumina Genome Analyzer SAN DIEGO--(Business Wire)-- Illumina (NASDAQ: ILMN) today announced that the November 6, 2008 issue of Nature published sequencing results of the first Yoruban human genome. The study was completed by Illumina scientists and collaborators at the Wellcome Trust Sanger Institute and generated greater than 30x average coverage of the genome. Four million single-nucleotide polymorphisms (SNPs), including one million novel SNPs, and 400,000 structural variants were identified. The Yoruban study and two other papers--by researchers at Beijing Genomics Institute (BGI) and Washington University--featured in the same November 6 issue of Nature all used the Illumina Genome Analyzer to complete the sequencing studies.

Open-source Analysis Tool enables Rapid Annotation of Metagenomes

The study of microbial communities from environmental samples, known as metagenomics, has been propelled forward by technological advancements in high-throughput, low-cost sequencing such as 454’s Genome Sequencer FLX System. With the recent use of sequencing approaches for metagenomic analysis, the major research challenges have shifted from generating to analyzing data. To resolve these analysis bottlenecks, a team of researchers from Argonne National Laboratory, The University of Chicago, and San Diego State University have developed an open source system for automated processing of metagenomic sequence data. The resource, designed specifically for data files generated by the 454 Sequencing platform, generates phylogenetic and functional summaries of the genomes by comparing the sequence against protein and nucleotide databases.

Open-source Analysis Tool enables Rapid Annotation of Metagenomes

BRANFORD, Conn.--(BUSINESS WIRE)--Nov 20, 2008 - The study of microbial communities from environmental samples, known as metagenomics, has been propelled forward by technological advancements in high-throughput, low-cost sequencing such as 454's Genome Sequencer FLX System. With the recent use of sequencing approaches for metagenomic analysis, the major research challenges have shifted from generating to analyzing data. To resolve these analysis bottlenecks, a team of researchers from Argonne National Laboratory, The University of Chicago, and San Diego State University have developed an open source system for automated processing of metagenomic sequence data. The resource, designed specifically for data files generated by the 454 Sequencing platform, generates phylogenetic and functional summaries of the genomes by comparing the sequence

Applied Biosystems Asks the Life Science Industry, "What Would You Do With a $10K Genome?"

As part of its commitment to promote basic research in the life sciences, Applied Biosystems Inc. (ABI) today announced the creation of a grant program for genomic, epigenomic and transcriptome studies. The $10K Genome Grant Program is based on the concept of sequencing an entire genome for $10,000. Applied Biosystems is launching this program to inspire new genomic sequencing studies on next-generation sequencing technology. By extending the SOLiD

Applied Biosystems Asks the Life Science Industry, "What Would You Do With a $10K Genome?"

As part of its commitment to promote basic research in the life sciences, Applied Biosystems Inc. (NYSE:ABI) today announced the creation of a grant program for genomic, epigenomic and transcriptome studies. The $10K Genome Grant Program is based on the concept of sequencing an entire genome for $10,000. Applied Biosystems is launching this program to inspire new genomic sequencing studies on next-generation sequencing technology. By extending the SOLiD(TM) System into other critical applications, such as RNA and epigenetic analysis, researchers will be able to advance the use of genomic data for clinical research and personalized medicine. Grant submissions are due by December 31, 2008. Results will be announced in February 2009.

Applied Biosystems Asks the Life Science Industry, "What Would You Do With a $10K Genome?"

FOSTER CITY, Calif.-- (BUSINESS WIRE) -- As part of its commitment to promote basic research in the life sciences, Applied Biosystems Inc. (NYSE:ABI) today announced the creation of a grant program for genomic, epigenomic and transcriptome studies. The $10K Genome Grant Program is based on the concept of sequencing an entire genome for $10,000. Applied Biosystems is launching this program to inspire new genomic sequencing studies on next-generation sequencing technology. By extending the SOLiD

Applied Biosystems Asks the Life Science Industry, "What Would You Do With a $10K Genome?"

FOSTER CITY, Calif.--(BUSINESS WIRE)--As part of its commitment to promote basic research in the life sciences, Applied Biosystems Inc. (NYSE:ABI) today announced the creation of a grant program for genomic, epigenomic and transcriptome studies. The $10K Genome Grant Program is based on the concept of sequencing an entire genome for $10,000. Applied Biosystems is launching this program to inspire new genomic sequencing studies on next-generation sequencing technology. By extending the SOLiD

Applied Biosystems Asks the Life Science Industry, "What Would You Do With a $10K Genome?"

FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct 27, 2008 - As part of its commitment to promote basic research in the life sciences, Applied Biosystems Inc. (NYSE:ABI) today announced the creation of a grant program for genomic, epigenomic and transcriptome studies. The $10K Genome Grant Program is based on the concept of sequencing an entire genome for $10,000. Applied Biosystems is launching this program to inspire new genomic sequencing studies on next-generation sequencing technology. By extending the SOLiD(TM) System into other critical applications, such as RNA and epigenetic analysis, researchers will be able to advance the use of genomic data for clinical research and personalized medicine. Grant submissions are due by December 31, 2008. Results will be announced in February 2009.

Costs plummeting for human genome sequencing

The relatively low cost of sequencing the genome of a Chinese man and an African man brings ever closer the prospect that average people can see their full genetic blueprint, according to separate studies published this week in the journal Nature.

Illumina announces breakthrough human genome sequencing studies

Illumina (NASDAQ: ILMN) has announced the sequencing results of the first Yoruban human genome. The study, published in the 6 November 2008 issue of Nature was completed by Illumina scientists and collaborators at the Wellcome Trust Sanger Institute and generated greater than 30x average coverage of the genome.

New Acquisition Expands Sequencing Install Base to 37 Illumina Genome Analyzers

Illumina, Inc. has announced that the Wellcome Trust Sanger Institute has purchased 11 additional Genome Analyzers, increasing the organization's total number of the Illumina sequencing platform to 37.

New Acquisition Expands Sequencing Install Base to 37 Illumina Genome Analyzers

SAN DIEGO--(BUSINESS WIRE)--Nov. 13, 2008--Illumina, Inc.(NASDAQ:ILMN) today announced that the Wellcome Trust Sanger Institute has purchased 11 additional Genome Analyzers, increasing the organization's total number of the Illumina sequencing platform to 37.

Study takes on mammoth genome sequencing

An international team led by a U.S. researcher has completed genome sequencing for an extinct animal, offering insight into its modern-day cousin.

Search took 0.02 seconds.